Xencor (NASDAQ:XNCR) Share Price Crosses Above 50 Day Moving Average – Here’s Why

15 Apr 2026, 18:42 by Amy Steele · The Cerbat Gem

Xencor, Inc. (NASDAQ:XNCR – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $11.99 and traded as high as $13.30. Xencor shares last traded at $12.07, with a volume of 771,730 shares.

Analysts Set New Price Targets

A number of equities analysts have recently commented on XNCR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $13.00 target price (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th. Barclays lifted their target price on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $24.38.

Check Out Our Latest Stock Analysis on Xencor

Xencor Price Performance

The business’s 50 day moving average is $12.00 and its two-hundred day moving average is $13.62. The firm has a market cap of $917.48 million, a P/E ratio of -10.09 and a beta of 0.99. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12.

Xencor (NASDAQ:XNCR – Get Free Report) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business had revenue of $28.24 million during the quarter, compared to the consensus estimate of $29.97 million. During the same quarter last year, the firm earned ($0.62) earnings per share. Xencor’s quarterly revenue was down 46.6% on a year-over-year basis. As a group, analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Insider Buying and Selling at Xencor

In other Xencor news, VP John R. Desjarlais sold 2,502 shares of Xencor stock in a transaction on Friday, March 6th. The shares were sold at an average price of $11.02, for a total value of $27,572.04. Following the completion of the sale, the vice president directly owned 263,831 shares of the company’s stock, valued at approximately $2,907,417.62. The trade was a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bassil I. Dahiyat sold 6,606 shares of Xencor stock in a transaction on Friday, March 6th. The shares were sold at an average price of $11.02, for a total transaction of $72,798.12. Following the completion of the sale, the chief executive officer directly owned 546,316 shares of the company’s stock, valued at approximately $6,020,402.32. This trade represents a 1.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 44,020 shares of company stock valued at $499,817. Corporate insiders own 5.23% of the company’s stock.

Institutional Investors Weigh In On Xencor

Several hedge funds and other institutional investors have recently bought and sold shares of XNCR. BVF Inc. IL increased its stake in Xencor by 160.3% in the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after purchasing an additional 4,393,579 shares in the last quarter. Legal & General Group Plc increased its stake in Xencor by 603.7% in the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after purchasing an additional 1,092,095 shares in the last quarter. State Street Corp increased its stake in Xencor by 22.7% in the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after purchasing an additional 833,423 shares in the last quarter. Jefferies Financial Group Inc. increased its stake in Xencor by 620.4% in the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after purchasing an additional 620,440 shares in the last quarter. Finally, RTW Investments LP increased its stake in Xencor by 8.9% in the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock valued at $103,763,000 after purchasing an additional 556,407 shares in the last quarter.

About Xencor

(Get Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.